Medicare now covers Zepbound for obesity and sleep apnea, making the costly drug more accessible.

Medicare will now cover Eli Lilly's Zepbound for patients with obesity and moderate-to-severe obstructive sleep apnea, expanding access to the costly drug. Previously not covered by Medicare or many other insurance plans, Zepbound was approved by the FDA in December. This decision could help many patients who were hesitant to use the drug due to its high cost.

2 months ago
14 Articles

Further Reading